Your search for ‘Smart & Biggar’ returned 2,497 results

As previously reported, on February 29, 2024, the Minister of Health introduced Bill C-64, An Act respecting pharmacare (Pharmacare Act)...

In March 2025, Health Canada published a Guide to the precision regulating authorities under the Food and Drugs Act.

Health Canada is launching a consultation on a proposed pilot program that would prioritize generic drug submissions involving domestic manufacturing within its regulatory review queue.

As we previously reported, Health Canada consulted on the framework for clinical trials, including on the new Clinical Trials Regulations and draft and updated guidance documents. Health Canada has now published a What we heard overview of the results of the consultation.

Our earlier article explained that the British Columbia government is using reimbursement policy to strongly encourage adoption of biosimilars for patients on provincial drug plans.

On October 25, 2023, the Patented Medicine Prices Review Board (PMPRB) announced that it will launch the first phase of consultations on new guidelines.

On October 21, 2025, the Patented Medicine Prices Review Board (PMPRB) announced the release of CompassRx (10th edition), an annual report that analyzes factors driving prescription drug expenditures in Canadian public drug plans.

On January 31, 2023, the Patented Medicine Prices Review Board (PMPRB) announced the latest edition of CompassRx, an annual report which contains information...

On June 26, 2024, the Patented Medicine Prices Review Board (PMPRB) released a Discussion Guide for its Phase 2 Consultations on its New Guidelines

On June 20, 2023, the Patented Medicine Prices Review Board (PMPRB) released a proposal to amend the Interim Guidance...

The PMPRB has just released revised draft Guidelines operationalizing the amended Patented Medicines Regulations, simultaneously beginning a 30-day consultation period.

On July 31, 2021, the Minister of Health provided notice of proposed amendments to the Food and Drug Regulations and the Medical Devices Regulations.

The US FDA has now approved a biosimilar version of infliximab, which is a chimeric human-mouse monoclonal antibody.

As previously reported, the Federal Court of Appeal dismissed two decisions relating to paliperidone palmitate (Janssen's INVEGA SUSTENNA)...

In the Patented Medicine Prices Review Board (PMPRB)'s June 2025 NEWSletter, Acting Chairperson Anie Perrault confirms that the PMPRB plans on publishing its final Guidelines in summer 2025.

An Order in Council published earlier this week fixed December 30, 2022, as the date on which legislation to extend the basic term of copyright protection in Canada from 50 years after...

The Federal Government of Canada has moved quickly to introduce amendments to the Copyright Act...

The most recent installment in a slew of high-damage award proceedings initiated by Canadian broadcasters, three Defendants implicated in the illicit sale of pre-loaded set-top boxes have been ordered to pay $38,810,000 in statutory damages pursuant to section 38.1 of the Copyright Act.